The prospective phase 4, open-label study began in January 2023 and includes 500 enrolled participants across the U.S. The medication is a once-a-day pill that treats inflammation caused by inflammatory bowel disease, ulcerative colitis and Chron’s.
According to the report, patients at UG have already begun to experience symptom relief after using the drug.
“I began taking the medication in August,” said Matt Baker, a 34-year-old patient in the trial with ulcerative colitis. “Ultimately, for me, all I’ve seen is an improvement in quality of life.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.